Patents Assigned to AstraZeneca
  • 4(Phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain of gastrointestinal disorders
    Patent number: 7253173
    Abstract: Compounds of general formula (I) wherein R1, R2 and R3 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared.
    Type: Grant
    Filed: November 5, 2003
    Date of Patent: August 7, 2007
    Assignee: AstraZeneca AB
    Inventors: William Brown, Andrew Griffin, Paul Jones, Daniel Pagé, Niklas Plobeck, Christopher Walpole
  • Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
    Publication number: 20070179188
    Abstract: The present invention relates to new compounds of formula (I), to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
    Type: Application
    Filed: February 15, 2005
    Publication date: August 2, 2007
    Applicants: AstraZeneca AB, NPS PHARMACEUTICALS, INC.
    Inventors: Louise Edwards, Methvin Isaac, Martin Johansson, Annika Kers, Johan Malmberg, Donald Mcleod, Alexander Minidis, Karin Staaf, Abdelmalik Slassi, Tomislav Stefanac, Thomas Stormann, David Wensbo, Tao Xin, Jalaj Arora
  • Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
    Patent number: 7250419
    Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: July 31, 2007
    Assignee: AstraZeneca AB
    Inventors: David Hardern, Anthony Ingall, Brian Springthorpe, Paul Willis, Simon Guile
  • CRISTALLINE AND AMORPHOUS FORM OF A TRIAZOLO (4,5-D) PYRIDIMINE COMPOUND
    Publication number: 20070173518
    Abstract: The invention provides new forms of a chemical compound of formula (I). The invention relates to forms of a chemical compound (I), in particular to crystalline and amorphous forms, more particularly four crystalline forms and an amorphous form. The invention further relates to processes for the preparation of such forms, to pharmaceutical compositions comprising the compound in crystalline and/or amorphous form and to therapeutic use of such forms.
    Type: Application
    Filed: October 3, 2005
    Publication date: July 26, 2007
    Applicant: AstraZeneca AB
    Inventors: Martin Bohlin, Steve Cosgrove, Bo Lassen
  • Ligands
    Publication number: 20070172420
    Abstract: A radioactive compound having the formula: and pharmaceutically-acceptable salts thereof, wherein R1 and Ar are as defined in the specification, enantiomers, in vivo-hydrolysable precursors, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to prepare them and uses of them for diagnostic and analytic purposes.
    Type: Application
    Filed: September 24, 2004
    Publication date: July 26, 2007
    Applicant: AstraZeneca AB
    Inventors: Peter Dorff, John Gordon, John Heys, Richard Keith, Dennis Mccarthy, Mark Smith, Eifion Phillips
  • Method for determining release of a peptide from a sustained release polylactide formulation
    Patent number: 7247491
    Abstract: A method for determining the release of a peptide from a sustained release polylactide formulation which can be carried out in a shorter time than a real-time method by accelerating the release of the peptide from the formulation. It can be used to discriminate between batches of formulations for quality control purposes and to discriminate between formulations, for example, having different drug loadings.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: July 24, 2007
    Assignee: AstraZeneca AB
    Inventors: Brian Collingwood Clark, David Michael Cross, Paul Richard Gellert, Rodney Simon Kittlety
  • Thienopyrroles as antagonists of gnrh
    Publication number: 20070167428
    Abstract: The invention relates to a group of novel thieno-pyrrole compounds of Formula (I) wherein: R1, R2, R3, R4 and R5 are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.
    Type: Application
    Filed: February 17, 2005
    Publication date: July 19, 2007
    Applicant: ASTRAZENECA AB
    Inventors: Jean-Claude Arnould, Craig Harris, Paul Jones
  • Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
    Patent number: 7244850
    Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof: Formula (I) wherein R1, R2, RF1, RF2 and Z are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: July 17, 2007
    Assignee: AstraZeneca AB
    Inventors: Daniel Pagé, Christopher Walpole, Hua Yang
  • Piperidine Derivatives and Their Use as Modulators of Chemokine Receptor Activity (Especially CCR5)
    Publication number: 20070161646
    Abstract: Compounds of formula (I): wherein L is CH or N; M is CH or N; provided that L and M are not both CH; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).
    Type: Application
    Filed: March 16, 2007
    Publication date: July 12, 2007
    Applicant: ASTRAZENECA AB
    Inventor: Howard Tucker
  • Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof
    Publication number: 20070161619
    Abstract: Compounds of general formula: wherein n, R1, R2, R3, R4 and Ar are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
    Type: Application
    Filed: February 2, 2005
    Publication date: July 12, 2007
    Applicant: ASTRAZENECA AB
    Inventors: Yun-Jin Hu, Miroslaw Tomaszewski, Christopher Walpole
  • Amidino derivatives and their use as thrombin inhibitors
    Patent number: 7241757
    Abstract: There is provided compounds of formula I wherein R1, Rx, Y, Ry, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.
    Type: Grant
    Filed: April 2, 2004
    Date of Patent: July 10, 2007
    Assignee: AstraZeneca AB
    Inventors: Tord Inghardt, Olle Karlsson, Marcel Linschoten, Jan-Erik Nyström
  • Phenylalkyloxy-phenyl derivatives
    Patent number: 7241923
    Abstract: The present invention relates to certain phenalkyloxy-phenyl derivatives of formula (I) and analogs, to a process for preparing such compounds, having the utility in clinical conditions associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: May 30, 2003
    Date of Patent: July 10, 2007
    Assignee: Astrazeneca AB
    Inventors: Jonas Fagerhad, Lanna Li, Lindstedt Alstermark Eva-Lotte
  • 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
    Patent number: 7241764
    Abstract: Compounds of general formula:[Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, and R3 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared.
    Type: Grant
    Filed: November 5, 2003
    Date of Patent: July 10, 2007
    Assignee: AstraZeneca AB
    Inventors: William Brown, Andrew Griffin
  • Chemical compounds
    Patent number: 7238811
    Abstract: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
    Type: Grant
    Filed: May 13, 2003
    Date of Patent: July 3, 2007
    Assignee: AstraZeneca AB
    Inventors: Aaron Rigby, Hitesh Sanganee, Brian Springthorpe, Louise Lawrence
  • G-protein coupled receptor
    Patent number: 7238780
    Abstract: The present invention is directed to a novel neurotensin-like receptor expressed in the central nervous system of humans. The invention encompasses the receptor protein as well as nucleic acids encoding the protein. In addition, the invention is directed to methods and compositions which utilize the receptor.
    Type: Grant
    Filed: July 14, 2004
    Date of Patent: July 3, 2007
    Assignee: Astrazeneca Canada Inc.
    Inventors: Sultan Ahmad, Jack Cao, Dajan O'Donnell, Philippe Walker
  • Piperidine derivatives and their use as modulators of chemokine (especially CCR3) activity
    Patent number: 7238691
    Abstract: The invention provides a compound of formula (I): T is C(O) or S(O)2; W is CH2, (CH2)2, CH(CH3), CH(CH3)O or cyclopropyl; X is O, CH2, C(O), S, S(O), S(O)2 or NR3; m is 0 or 1; R1 is optionally substituted aryl or optionally substituted heterocyclyl; R2 is alkyl (optionally substituted by OH), cycloalkyl, optionally substituted aryl or optionally substituted heterocyclyl; that are modulators of chemokine (especially CCR3) activity and are especially useful for treating asthma and/or rhinitis.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: July 3, 2007
    Assignee: AstraZeneca AB
    Inventors: Hitesh Sanganee, Brian Springthorpe
  • Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them
    Patent number: 7238684
    Abstract: The present invention relates to compounds of formula (I): wherein Rv, R1, R2, Rx, Ry, R3, R4, R5, R6, Rz and v are as defined within; pharmaceutically acceptable salts, solvates, solvates or such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.
    Type: Grant
    Filed: April 23, 2003
    Date of Patent: July 3, 2007
    Assignee: AstraZeneca AB
    Inventors: Ingemar Starke, Mikael Ulf Johan Dahlstrom, Mats Peter Nordberg, Suzanne Alenfalk, Andreas Christer Wallberg, Stig Jonas Bostrom
  • Novel fused triazolones and the uses thereof
    Publication number: 20070149560
    Abstract: This invention relates to novel compounds having the structural diagram (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    Type: Application
    Filed: March 10, 2004
    Publication date: June 28, 2007
    Applicant: AstraZeneca AB
    Inventors: Susan Ashwell, Jayachandran Ezhuthachan, Paul Lyne, Nicholas Newcombe, Martin Pass, Vibha Oza, Mei Su, Dorin Toader, Dingwei Yu, Yan Yu
  • Guanidine and amidine acid derivatives and analogs and methods of using the same
    Publication number: 20070149614
    Abstract: The present invention relates to certain novel guanidine or amidine acid derivatives and analogs, to a process for preparing such compounds, having the utility in clinical conditions associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Application
    Filed: December 19, 2006
    Publication date: June 28, 2007
    Applicant: AstraZeneca AB
    Inventors: Krister Bamberg, Lanna Li
  • Device for holding a blister pack
    Patent number: D546198
    Type: Grant
    Filed: March 9, 2006
    Date of Patent: July 10, 2007
    Assignee: AstraZeneca AB
    Inventors: John Currie, Christopher Harris, Derek Shaw